Mirum Pharmaceuticals (MIRM) PT Raised to $81 at Citizens JMP
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/4/2026
- Wall Street ends lower as Middle East tensions escalate
- Broadcom results, guidance beat on soaring AI chip sales; stock slips after hours
- Broadcom's sales and AI chip forecast comes in below expectations, shares tumble
- SpaceX sets IPO price at $135 ahead of roadshow in break with Wall Street norms
- Oil gains as Middle East hostilities flare
- Morgan Stanley lifts MU and SNDK targets, sees 2-3 years of tight memory supply
- Navitas showcases 800V power delivery board at NVIDIA MGX ecosystem event
- Inotiv files for bankruptcy with $65 million financing commitment
- Broadcom results, guidance beat on soaring AI chip sales; stock slips after hours
- Wall Street ends lower as Middle East tensions escalate
- After-Hours Stock Movers: AVGO, CRWD, FIVE, AI, TLYS, NTSK,
- After-Hours Stock Movers: PANW, CRWD, ZS, GTLB, ULTA
- After-Hours Stock Movers: HPE, CRDO, FULC, ABVX, MCHP
- After-Hours Stock Movers: DELL, MDB, AEO, NTAP, GAP, S, ADSK
- After-Hours Stock Movers: CRM, MRVL, SNOW, HPQ, DDOG, MDB, P, SNPS, BRZE, NCNO
Stifel Resumes Mirum Pharmaceuticals (MIRM) at Buy, PT $89, 'stands out in what remains a discerning biotech tape'
August 11, 2025 5:48 AM EDTStifel analyst James Condulis resumes coverage on Mirum Pharmaceuticals (NASDAQ: MIRM) with a Buy rating and a price target of $89.00.
The analyst comments "We're resuming coverage of Mirum with a Buy rating and an $89 target price. Mirum is a unique rare disease biotech with: (1) a cash-flow... More
